106 related articles for article (PubMed ID: 26001120)
21. [Recombinant therapeutic vaccines against cancer of the uterine cervix].
Berumen J; Villegas N
Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250
[TBL] [Abstract][Full Text] [Related]
22. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
23. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
24. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
25. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.
Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G
J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
Ohlschläger P; Quetting M; Alvarez G; Dürst M; Gissmann L; Kaufmann AM
Int J Cancer; 2009 Jul; 125(1):189-98. PubMed ID: 19358269
[TBL] [Abstract][Full Text] [Related]
27. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
28. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
29. Immunology of human papillomavirus infection in lower genital tract neoplasia.
Man S; Fiander A
Best Pract Res Clin Obstet Gynaecol; 2001 Oct; 15(5):701-14. PubMed ID: 11563868
[TBL] [Abstract][Full Text] [Related]
30. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
31. Cervical cancer vaccines: emerging concepts and developments.
Da Silva DM; Eiben GL; Fausch SC; Wakabayashi MT; Rudolf MP; Velders MP; Kast WM
J Cell Physiol; 2001 Feb; 186(2):169-82. PubMed ID: 11169454
[TBL] [Abstract][Full Text] [Related]
32. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
Tomson TT; Roden RB; Wu TC
Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
[TBL] [Abstract][Full Text] [Related]
34. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
35. Papillomavirus-like particle vaccines for cervical cancer.
Schiller JT
Mol Med Today; 1999 May; 5(5):209-15. PubMed ID: 10322313
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
37. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
[TBL] [Abstract][Full Text] [Related]
38. Gearing up T-cell immunotherapy in cervical cancer.
Chauhan SR; Bharadwaj M
Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
[TBL] [Abstract][Full Text] [Related]
40. Progress in the use of immunotherapy to treat uterine cervical cancer.
De Lorenzo BH; Ramos Mde C; Michelin MA; Murta EF
Tumori; 2009; 95(1):1-7. PubMed ID: 19366048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]